首頁 › 瀰漫性大B細胞淋巴瘤 › 俄亥俄州 › Cincinnati
Cincinnati, OH 的 瀰漫性大B細胞淋巴瘤 臨床試驗
11 項針對 瀰漫性大B細胞淋巴瘤 的研究正在 Cincinnati（約 30 英里範圍內）及其周邊地點尋找參與者。開啟研究以查看參與資格及聯絡研究團隊的方式。
官方研究文本（英文）
正在為研究招募對象嗎？將此頁面置頂展示 — $99 / 30 天 →
Consolidation of First-Line MRD+ Remission With Cema-cel in Patients With LBCL
招募中2 期
- Oncology Hematology Care - Kenwood, Cincinnati
- University of Cincinnati Medical Center, Cincinnati
Pharmacokinetic Study of Venetoclax Tablets Crushed and Dissolved Into a Solution
招募中觀察性研究
- Cincinnati Children's Hospital Medical Center, Cincinnati
Testing the Effectiveness of a Combination Targeted Therapy (ViPOR) for Patients With Relapsed and/or Refractory Aggressive B-cell Lymphoma
招募中2 期
- University of Cincinnati Cancer Center-UC Medical Center, Cincinnati
- University of Cincinnati Cancer Center-West Chester, West Chester · 距離 15 英里
A Study to Evaluate Zilovertamab Vedotin (MK-2140) Combination With Rituximab Plus Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) in Participants With Previously Untreated DLBCL (MK-2140-010)
招募中3 期
- Oncology_Hematology Care Clinical Trials, LLC (OHC) ( Site 8002), Cincinnati
A Study of Zilovertamab Vedotin (MK-2140) in Combination With Standard of Care in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (rrDLBCL) (MK-2140-003)
招募中2/3 期
- Saint Elizabeth Medical Center Edgewood ( Site 0165), Edgewood · 距離 8 英里
A Clinical Study of Zilovertamab Vedotin (MK-2140) Plus Rituximab Plus Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Polatuzumab Vedotin Plus R-CHP in People With Diffuse Large B-cell Lymphoma (DLBCL) (MK-2140-011/waveLINE-011)
招募中2 期
- University of Cincinnati Medical Center ( Site 0156), Cincinnati
- Saint Elizabeth Medical Center Edgewood ( Site 0141), Edgewood · 距離 8 英里
Study of Rondecabtagene Autoleucel in Aggressive Large B-Cell Lymphoma
招募中1/2 期
- University of Cincinnati (UC) Physicians Company, LLC, Cincinnati
A Study to Investigate Ronde-cel Versus Investigator's Choice CD19 CAR T-Cell Therapy
招募中3 期
- Oncology Hematology Care Clinical Trials, Cincinnati
- University of Cincinnati, Cincinnati
A Study of NX-5948 in Adults With Relapsed/Refractory B-cell Malignancies
招募中1 期
- University of Cincinnati Medical Center, Cincinnati
Study of Oral Administration of LP-168 in Patients With Relapsed or Refractory B-cell Malignancies.
招募中1 期
- University of Cincinnati, Cincinnati
Safety and Efficacy of KRT-232 in Combination With Acalabrutinib in Subjects With R/R DLBCL or R/R CLL
招募中1/2 期
- University of Cincinnati, Cincinnati
其他城市的 瀰漫性大B細胞淋巴瘤 試驗
- New York City, NY21 項研究
- Baldwin Park, CA19 項研究
- Chicago, IL18 項研究
- Houston, TX17 項研究
- Los Angeles, CA17 項研究
- Boston, MA16 項研究
- Milwaukee, WI16 項研究
- Nashville, TN15 項研究
- Portland, OR15 項研究
- Philadelphia, PA15 項研究
- Durham, NC14 項研究
- Dallas, TX13 項研究
Cincinnati 的其他研究
- 非小細胞肺癌35 項研究
- 癌症（所有類型）27 項研究
- 乳癌25 項研究
- 心臟衰竭24 項研究
- 大腸直腸癌21 項研究
- 急性髓系白血病20 項研究
- 轉移性癌症20 項研究
- 卵巢癌19 項研究
- 肺癌19 項研究
- 肥胖症19 項研究
- 前列腺癌18 項研究
- 多發性骨髓瘤17 項研究
資料來源：ClinicalTrials.gov，擷取日期 2026年10月5日。各研究自行設定資格標準；由研究團隊決定參與者資格。